Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

Clinical trial NCT06420063 · RECRUITING

Trial details

NCT number: NCT06420063
Sponsor: Essen Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

AML Acute Myeloid Leukemia AML, Adult Recurrent AML, Adult

Start date: 2024-07-10
Primary completion: 2025-12-10
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.